OpenAlex
PricingAboutJobs
Log inGet started
Work

A Phase II Study of Erlotinib as First-Line Treatment in Japanese Advanced NSCLC Patients Harboring EGFR Mutations

HTML

Year: 2012
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
DOI: 10.1016/s0923-7534(20)33854-0
Authors: A. Horiike, M. Nishio, K. Goto, N. Yamamoto, K. Chikamori, M. Maemondo, T. Hida, N. Katakami, T. Tamura
Institutions: Miyagi Prefectural Hospital Organization, National Cancer Center Hospital East, Saitama Medical University, Tohoku University, National Cancer Center Hospital, Niigata University Medical and Dental Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research
Language: English

Topic: Lung Cancer Treatments and Mutations
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: erlotinib, non-small cell lung cancer, EGFR mutation, first-line therapy, Japanese patients, tyrosine kinase inhibitors, progression-free survival, overall survival, neutropenia, drug toxicity
SDG: Good health and well-being

Open Access status: bronze
OpenAlex ID: W3000286752
FWCI: 0.735
Cites:
Cited by: 4
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms